Vichem performs advanced medicinal chemistry in the kinase inhibitory field based on its unique, in-house developed, Nested Chemical Library™ (NCL) technology. The NCL was designed on the platform of an up-to-date knowledge base what we have built up from the knowledge accumulated in our recent 20 years of kinase inhibitory chemistry. Our library is organized around 108 core structures and more than 300 scaffolds, and contains inhibitors against 124 kinases, providing the most diverse kinase inhibitory library available for drug research.
Utilizing our NCL/ Masterkey/Pharmacophore/Scaffold hopping technologies we can provide patentable lead compounds against selected kinases in five research cycles in about one year. Using our KinaTor™ technology we can perform selectivity profiling and off target identification. We can develop preclinical candidates with lead optimization for efficacy and ADMET in an additional 2 years. The medicinal chemistry research team of Vichem is highly specialized in developing drug candidate protein kinase inhibitors (PKI).
Vichem has lead compounds and/or early preclinical candidates for Tuberculosis, Influenza, AIDS and 5 pathological kinase targets. Vichem established partnership with various European, American and Japanese institutions and companies, coordinates a European FP6 Tuberculosis project and participates in 5 European programs.
Specialties
Vichem is a Hungarian biotech research company focusing on signal transduction therapy with kinase inhibitors.
